安徽华恒生物科技股份有限公司 关于发行境外上市股份（H股）备案申请材料获 中国证监会接收的公告

Core Points - Anhui Huaheng Biological Technology Co., Ltd. has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange [1] - The application materials for the overseas listing have been accepted by the China Securities Regulatory Commission (CSRC) [1][2] - The company is awaiting approvals from relevant regulatory bodies, including the CSRC, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating potential uncertainties in the process [2] Summary by Sections - Company Actions - The company submitted its application for H-share issuance and listing on September 30, 2025 [1] - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - Regulatory Status - The application has been accepted by the CSRC, marking a significant step in the listing process [1] - The company must still obtain approvals from various regulatory bodies, which introduces uncertainty [2] - Investor Communication - The company commits to timely information disclosure regarding the progress of the application [2]